Sidley Represents Lead Investors in US$200 Million Financing by NiKang Therapeutics
June 3, 2021
Related Professionals
Offices
Stay Up To Date
Sidley is representing the lead investors in NiKang Therapeutics Inc.’s US$200 million equity financing pursuant to the issuance and sale of its Series C Preferred Stock. The lead investors were HBM Healthcare Investments, Cormorant Asset Management, and Octagon Capital Advisors with participation from a syndicate of other leading institutional investors. NiKang is a clinical-stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs.
The Sidley team is led by Mehdi Khodadad (M&A and Private Equity) and includes Anthony Friedman, Patrick Sims, and Max Chaffetz (M&A and Private Equity).
This website uses cookies. Analytical cookies help us improve our website by providing insight on how visitors interact with our site, and necessary cookies which the website needs to function properly.
Necessary Cookies
The website cannot function properly without these necessary cookies, and they can only be disabled by changing your browser preferences. To learn more about these cookies, how we use them on our website, and how to revise your cookie settings, please view our cookie policy.
You have successfully set your edition to United States. Would you like to make this selection your default edition?
*Selecting a default edition will set a cookie.
This website uses cookies. Analytical cookies help us improve our website by providing insight on how visitors interact with our site, and necessary cookies which the website needs to function properly.
Necessary Cookies
The website cannot function properly without these necessary cookies, and they can only be disabled by changing your browser preferences. To learn more about these cookies, how we use them on our website, and how to revise your cookie settings, please view our cookie policy.